**7. Treatment**

With all the risk factors and in the case of dyslipidemia and to reduce the global mortality of patients with mental illness we should consider lipid goal of therapy for these patients. The benefits and risks of different therapeutic agents used in the treatment of dyslipidemia and its comorbidities should be considered in the context of the patient's psychiatric condition and treatment.

### **7.1 Drugs**

ATP III recommends a multifaceted lifestyle approach to reduce risk for coronary heart disease (CHD). This approach is designated therapeutic lifestyle changes (TLC). Some patients whose short-term or long-term risk for CHD is high will require LDL-lowering drugs in addition to TLC. When drugs are prescribed, attention to TLC should always be maintained and reinforced. Available drugs are:

abuse. Keep in mind that psychotropic medications other than antipsychotic drugs such as some antidepressants and mood stabilizers may link to weight gain. The baseline


If any abnormalities are identified, first, patients should be informed of their condition and supported in making lifestyle changes to adopt a healthier diet and increase physical activity. Psychiatrists should not hesitate to refer the patient to the appropriate health care

Even for patients free of metabolic disorders, monitor potential risk factors. Weight gain may not be dose-dependent and patients with low body mass index at baseline may be particularly vulnerable to weight gain. Glucose and lipid metabolism abnormalities may

The patient's weight should be reassessed at 4, 8, and 12 weeks after initiating or changing SGA therapy and quarterly thereafter at the time of routine visits. If a patient gains > 5% of his or her initial weight at any time during therapy, one should consider switching the medication. When switching, consideration should be given to all aspects of the individual's condition, the comparative risks and benefits of changing medications, and the individual's response to medication in managing the primary symptoms of the mental illness. In some

Fasting plasma glucose, lipid profile, and blood pressure should also be assessed 3 months after initiation of medication. Thereafter, blood pressure, plasma glucose values, lipid profile should be obtained annually or more frequently in those who have a higher baseline

With all the risk factors and in the case of dyslipidemia and to reduce the global mortality of patients with mental illness we should consider lipid goal of therapy for these patients. The benefits and risks of different therapeutic agents used in the treatment of dyslipidemia and its comorbidities should be considered in the context of the patient's psychiatric condition

ATP III recommends a multifaceted lifestyle approach to reduce risk for coronary heart disease (CHD). This approach is designated therapeutic lifestyle changes (TLC). Some patients whose short-term or long-term risk for CHD is high will require LDL-lowering drugs in addition to TLC. When drugs are prescribed, attention to TLC should always be

assessments include:


cardiovascular disease


occur without weight gain.

**6.2.2 Follow-up monitoring** 

**7. Treatment** 

and treatment.

**7.1 Drugs** 


professional or specialist knowledgeable about these disorders.

cases, cost and availability may also be a consideration.

maintained and reinforced. Available drugs are:

risk for the development of diabetes, dyslipidemia or hypertension.


All these drugs reduced major coronary events, CHD deaths but we have to be carefull with their side effects and contraindications when prescribing these drugs.

Beyond the underlying risk factor, therapies directed against the lipid and nonlipid risk factors of the metabolic syndrome will reduce CHD risk.

The management of dyslipidemia in mental health is defined, as recommended by the Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes by:

The lifestyle interventions with diet, increased physical activity and smoking cessation. They are the firs-line treatments to decrease the risk for cardiovascular disease in patient with metabolic syndrome.
